1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On June 22, 2026, SolarMax Technology received a Nasdaq notice that it does not meet the Nasdaq Capital Market requirement to maintain at least $35 million in market value of listed securities. The company has 180 calendar days, until December 21, 2026, to regain compliance, and this notice is in addition to an earlier Nasdaq notice about its $1.00 minimum bid price. If the company does not regain compliance by then, it will receive written notice that its securities are subject to delisting.
Nasdaq notice dated June 22, 2026, cites Rule 5550(b)(2), the $35 million minimum market value of listed securities.
Compliance period runs 180 calendar days and expires December 21, 2026.
Regaining compliance requires market value of at least $35 million for a minimum of ten consecutive business days.
Separate from the previously announced Nasdaq notice for failing the $1.00 minimum bid price.
Monopar Therapeutics said the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to ALXN1840 (tiomolibdate choline), its late-stage candidate for Wilson disease. The designation gives the company the potential to receive a pediatric Priority Review Voucher if the drug is approved, but the filing does not say whether approval will come or whether a voucher will be awarded.
FDA granted Rare Pediatric Disease designation to ALXN1840 for Wilson disease, announced June 30, 2026
The designation provides potential eligibility for a pediatric Priority Review Voucher at the time of NDA approval
The filing does not report revenue, earnings, or guidance
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.